US Pharma MarketingTakeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year. The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).
The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).
Source: FiercePharma